DATOM Record · DTM-2026-0703-2E
GLP-1 weight-loss drugs cause you to lose muscle while you lose weight.
DATOM looked at 51 studies that directly tested this claim. Of those, 44 (86%) support the idea that GLP-1 weight-loss drugs cause you to lose muscle while you lose weight; 7 (14%) point the other way. That headline count leans clearly one way — but the verdict below is Contested, and the gap between those two facts is the point of this record. Counting studies treats 51 findings as 51 independent tests, and they are not: many share authors, labs and cohorts. Once they are weighted and grouped by how independent they actually are, the honest estimate carries a range rather than a single number, and that range runs from 54.6% to 75.0%. A claim is only called Supported when the bottom of its range clears 55%. This one comes in at 54.6% — it misses by four tenths of a percentage point. So the evidence leans toward the claim and may well end up supporting it, but as it stands it is not settled enough to say so.
Exact claim checked GLP-1 receptor agonist therapy at clinically approved doses reduces skeletal muscle mass during weight loss in overweight and obese adults, as measured by lean body mass or appendicular skeletal muscle mass over a treatment period of 12 to 68 weeks.
Domainclinical medicine
Contested means the evidence leans toward this claim without settling it. It does not mean the claim was refuted, and it does not mean the studies are evenly split — most of the clear findings do point one way. It means that once the evidence is weighted for how independent it really is, the honest range still crosses the line between “leaning” and “supported”, so calling it Supported would overstate what is known. New independent studies could move this in either direction.
Evidence Grade
Grade B · solid evidence base, wide range
Is this medical advice? No. This looks at whether current evidence supports one specific claim. It does not cover safety, dosing, or side effects, and it is not a recommendation to use or avoid any medication. Talk to a doctor before making a decision about your health.
What the evidence looks like
Of the 51 studies that directly tested this claim:
The studies · a sample of the evidence base, the three that weigh most first
- SupportsOpportunities to optimize lifestyle interventions in combination with glucagon-like peptide-1-based therapy.. Satya Dash, 2024, n/a. doi.org/10.1111/dom.15829
- SupportsWeighing the risk of GLP-1 treatment in older adults: Should we be concerned about sarcopenic obesity?. Konstantinos Prokopidis et al., 2025, n/a. doi.org/10.1016/j.jnha.2025.100652
- SupportsThe impact of weight loss on fat-free mass, muscle, bone and hematopoiesis health: Implications for emerging pharmacotherapies aiming at fat reduction and lean mass preservation.. Konstantinos Stefanakis et al., 2024, n/a. doi.org/10.1016/j.metabol.2024.156057
Show the other 11
- ConditionalBimagrumab plus semaglutide alone or in combination for the treatment of obesity: a randomized phase 2 trial. S. Heymsfield et al., 2026, n/a. doi.org/10.1038/s41591-026-04204-0
- ConditionalDionysus or apollo, skeletal muscle mass changes in type 2 diabetes with sarcopenia receiving GLP-1 receptor agonist: systematic review and meta-analysis. Yanying Wang et al., 2025, n/a. doi.org/10.1186/s13098-025-01877-4
- ConditionalOral Nutritional Supplements and Body Composition Outcomes Among GLP-1 Receptor Agonist Users: Real-World Evidence.. Kurt Hong et al., 2026, n/a. doi.org/10.2147/DMSO.S574765
- ConditionalAdvantage of Semaglutide: Comprehensive Analysis of Metabolic Impact of Semaglutide‐Treated and Pair‐Fed Rats. Suyeun Byun et al., 2025, n/a. doi.org/10.1002/cph4.70083
- ConditionalEffects of liraglutide treatment for 35-days on total and regional fat free, lean, and bone mass, and on the Myostatin-Activin-Follistatin-IGF-1 axes: a secondary analysis of a randomized placebo-controlled crossover study.. Valeria Gutierrez de Piñeres et al., 2026, n/a. doi.org/10.1016/j.diabres.2026.113113
- ConditionalPreserving the Metabolic Engine: Muscle as the Therapeutic Target for Cardiovascular Prevention in Obesity Pharmacotherapy.. Fabian Sanchis-Gomar et al., 2025, n/a. doi.org/10.1007/s11886-025-02334-4
- ConditionalMoving beyond the scale: musculoskeletal risks, evidence gaps and emerging combination strategies to optimize the quality of weight loss pharmacotherapy in older adults. Kieran F. Reid et al., 2025, n/a. doi.org/10.3389/fragi.2025.1640030
- ConditionalSEMAGLUTIDE AND BODY COMPOSITION: A NARRATIVE REVIEW OF ITS EFFECTS ON LEAN MASS AND STRATEGIES FOR PRESERVATION. Anna Tomasiewicz et al., 2025, n/a. doi.org/10.31435/ijitss.3(47).2025.4067
- ConditionalThe Influence of Glucagon-like Peptide-1 Receptor Agonists and Other Incretin Hormone Agonists on Body Composition.. Lampros Chrysavgis et al., 2025, n/a. doi.org/10.3390/ijms262412130
- ConditionalWeight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension. J. Wilding et al., 2022, n/a. doi.org/10.1111/dom.14725
- ConditionalMuscle health in the modern era of incretin-based therapies.. Giuseppe De Girolamo et al., 2026, n/a. doi.org/10.1111/eci.70155
Every study links to the original. The three highlighted weigh most. Some studies in the list bear on the claim only under certain conditions (tagged Conditional) and sit outside the 51 that directly tested it, which is why the sample and the bar above count different things. The complete evidence base is in the full Confidence Report.
• A dated entry, not a live feed. This record changes when DATOM re-examines the claim and publishes a dated revision; earlier evaluations stay in the record's history. · How DATOM checks a claim
DATOM is the public record of scientific claims, checked independently, updated as evidence changes.